Background: The adaptive immune system is involved in type 2 diabetes mellitus (T2DM),
of autoantibodies associated with T1DM. 8 In a mouse model, B cells appear to play an instrumental role in worsening insulin action via modulation of T cells and production of pathogenic IgG antibodies, indicating a role for adaptive immunity in the pathophysiology of T2DM. 4 Humans with obesity and T2DM have higher levels of antibody secretion and polyclonal B-cell activity. 9 Elevated polyclonal B-cell activity seen in T2DM and obesity may increase likelihood of developing autoantibodies by overwhelming immune checkpoints against autoimmunity, as has been proposed in the pathogenesis of lupus autoantibodies. 10 Autoantibodies have been detected in subgroups of participants with T2DM who were at increased risk for hypertension or cardiovascular complications (G-protein coupled receptors 11 ), who had maculopathy and macroalbuminuria (rho-kinases 12 ), and Charcot neuroarthopathy (type 2 collagen 13 ). In addition, IL-6 autoantibodies have been detected in sera from 2.5% of Danish participants with T2DM. 14 There is evidence of a role for the innate and adaptive immune systems in the development of T2DM specifically in Southwest American Indians (SAIs), a group in which T2DM and obesity are highly prevalent, but with low prevalence of GAD65 antibody and other known islet cell antibodies. [15] [16] [17] Markers of macrophage activation were associated with insulin action, 18 and elevated leukocyte count predicted worsening insulin action and the development of T2DM. 19 Serum concentrations of gamma globulin, a nonspecific measure of the humoral immune system, were also positively associated with development of T2DM in SAIs. 20 T-cell receptor complementarity determining region 3 length is shorter in SAI participants with T2DM and associated with increased risk of diabetes. 21 Many autoimmune diseases show an association with certain human leukocyte antigen (HLA) haplotypes, usually involving the major histocompatibility complex class II, which encodes for genes that are important for immune response regulation. 22 A single-nucleotide polymorphism (SNP) that tags an HLA haplotype (HLA-DRB1*16:02) protective for T2DM and associated with increased insulin secretion was identified in this SAI population. 15 These findings from animal models and both SAI and non-SAI populations may be interpreted as supporting a potential role for autoimmunity and suggests the presence of unidentified autoantibodies. As new therapies targeting the immune system emerge for treatment of T2DM, 23 new biomarkers reflecting autoimmunity (eg, autoantibodies) may be useful.
In this SAI population, we previously screened 9480 target proteins in a microarray in 18 individuals. 24 On the basis of specified statistical criteria or possible role in underlying biology of type diabetes, we then tested 70 of these proteins in a second confirmatory study in a moderately larger group (n = 90) identifying 14 as promising biomarkers. 24 However, in both initial exploratory studies, to maximize the potential difference between groups, we selected individuals with T2DM and without the protective SNP that tags the HLA-DRB1*16:02 haplotype for comparison with those with normal glucose regulation (NGR) and the presence of the protective haplotype. 24 Thus, prior studies were limited by small sample sizes and by the fact that it could not ascertained whether the identified autoantibodies were associated with T2DM, the protective SNP, or a combination. To further evaluate these autoantibodies, we tested the hypothesis that autoantibodies identified in our prior studies were associated withT2DM, independent of the protective SNP. We therefore conducted a frequency matched case-control study involving 476 cases with T2DM and 424 controls with NGR. this sample size achieved at least 90% power as described below.
| Measurement of antibodies
The reactivity of plasma samples to 14 target antigens ( were selected since they were significantly associated with participants with T2DM who lacked the protective HLA haplotype based on our prior study, 24 and the remaining 3 target proteins (LXR-alpha, interleukin 1 beta [IL1B], and IAPP) were marginally associated in the pilot study but were known to be biologically relevant to obesity and T2DM based on the literature. [27] [28] [29] Test plasma was previously stored at −70°C. All 14 antigens were produced in a baculovirus-insect cell expression system 30, 31 and captured on anti-glutathione S-transferase Samples were assayed in triplicate for each analyte with CV ranging between 2.7% to 3.3%.
| Additional covariates and fixed factors
Body mass index (BMI) (kg/m haplotype as previously described. 15 The A allele at rs9268852, which tags HLA-DRB1*16:02, was previously associated with decreased risk of T2DM
15
; participants were therefore classified as having the protective haplotype if they had a least one copy of the A allele at this genomic locus.
| Statistical analysis
All statistical analyses were performed using SAS software, version 9.3 (SAS Institute, Cary, North Carolina). On the basis of results from our prior study 24 and using a one-sided unpaired t test using the lowest A one-sided p-value was chosen to confirm the directionality of the relationships found in the prior 2 studies since we had deliberately chosen proteins with antibody levels more elevated among cases than controls.
Antibody MFI had a skewed distribution and LOG 10 transformation was applied. To assess for association between antibody level and T2DM status independent of any differences in sample storage time or potential nonspecific reactivity from the antibody assay, we adjusted MFI by storage time and background MFI (bovine serum albumin bound directly to beads and GST captured on anti-GST conjugated beads) by linear regression analysis and then used the remaining unexplained variance (ie, residuals) for subsequent analysis. For comparison of participant characteristics between cases and controls, two-sided P values were calculated using unpaired t, Wilcoxon rank-sum, and chi-squared tests where appropriate. An alpha level of 0.05 was chosen for these analyses. For comparison of antibodies between cases and controls, a one-tailed unpaired t test was used since proteins with antibody levels that were more elevated among cases than controls were deliberately chosen based on our prior studies 24 and confirmation of this relationship was sought in the present study. To account for multiple testing, the Bonferonni-corrected threshold of P < .0036
was used for testing of the 14 antibodies.
Using unconditional logistic regression, we calculated odds ratios (ORs) with 95% CIs for the associations between antibodies and T2DM. For these logistic regression models, we standardized continuous variables by using normalizing inverse Gaussian transformation of the ranks. The ORs were adjusted for age (continuous) and sex 3 | RESULTS
| Characteristics
Most cases had antibody assays from blood samples taken at the time of diagnosis of T2DM (82%), and the remaining cases (18%) had diabetes duration of less than 5 years (Table 1) . By the frequency matched sampling, the proportion of cases who were men were comparable in cases (50%) and controls (49%) (P = .61). There were fewer controls in the oldest age-decade (50-59 y) compared with cases due to availability of eligible controls (Table 1) increased production of autoantibodies, 33 we evaluated the association between age and autoantibodies and found that 12 of the 14 antibodies (PPARG2, UBE2M, LOC284912, TEAD4, PFDN2, MRPS7, OSBPL11, CBS, MAP2K3-B, LXR-alpha, IL1B, and IAPP) were weakly directly correlated with age (r ranging from 0.06 to 0.22, P < .05).
| Antibodies and T2DM
Anti-PFDN2 antibody (mean of LOG 10 MFI values) was greater among cases than controls (P = .0001), which was significant at the multipletesting corrected (Bonferonni) threshold of P < .0036 (Table 2) .
Anti-PPARG2 and anti-TEAD4 antibody MFI were nominally greater (P = .008 and P = .041, respectively) in cases than controls, but this
was not significant at the multiple-testing corrected threshold.
Logistic regression models were created to control for risk factors identified a priori. In these models, continuous variables (age, BMI, and antibodies) were rank standardized to a normal distribution and ORs were expressed per one SD change in these variables. Anti-PFDN2
antibody were associated with increased prevalence of T2DM in univariate analysis (OR 1.33; 95% CI, 1.15-1.54; P = .0001) and remained associated with increased prevalence of T2DM in different multivariate logistic regression models (Table 3 ). In the full model adjusting for age, sex, SAI heritage, BMI, and the protective SNP that tags HLA-DRB1*16:02, anti-PFDN2 antibody (OR 1.27; 95% CI, 1.09-1.49; P = .003) remained independently associated with increased prevalence for T2DM, (Table 3) . In this full model, the SNP that tags HLA-DRB1*16:02 (OR 0.61, 95% CI 0.40-0.93, p = 0.02) remained protective for T2DM, consistent with previous reports in this population. 15 The odds of T2DM were increased in the highest anti-PFDN2 antibody quintile by 66% (OR 1.66; 95% CI, 1.01-2.73; P = .046), compared with antibody and T2DM appeared to be driven largely by differences in the younger age groups (Figure 1 ). In the age groups 20 to 29 and 30 to 39 years, those with T2DM had significantly greater anti-PFDN2
antibody level than controls (P = .002 and P = .009, respectively), even after adjusting for age group, T2DM status, sex, SAI heritage, BMI, and HLA haplotype.
Taking as the cutoff, 2 standard deviations above the overall mean of the controls, 10.5% of individuals age 20 to 29 years were classified as positive, compared with 3.2% in the same age group (P = .03). Using a similar classification for the age group 30 to 39 years, 6.5% of cases and 3.2% of controls were positive, although not significantly different.
In the older age groups (40-49 and 50-59 y), the proportions of those who were positive were between 6.0% and 8.0% and proportions were not significantly different between cases and controls.
| Antibody and HLA haplotype
We evaluated whether the presence of the SNP protective for T2DM
that tags HLA-DRB1*16:02 was associated with antibody levels using Abbreviations: BMI, body mass index; SAI, Southwest American Indian; SNP, single-nucleotide polymorphism.
Models 1-4 are also adjusted for age and sex.
Anti-PFDN2 antibody and BMI were standardized to a normal distribution with SD = 1; ORs are given for a one SD difference in antibody level. n = 796 with complete data for all variables.
| DISCUSSION
We hypothesized that there were unidentified circulating autoantibodies in T2DM. PFDN2 and other protein targets were previously identified via a microarray experiment that was confirmed in a second sample via a microsphere-based experiment. 24 However, these experiments had a small sample and could not differentiate an association with T2DM from an association with the protective SNP that tags HLA-DRB1*16:02. 15 The current study involving a large sample in a well-defined population with detailed information on important risk factors demonstrated that T2DM is associated with elevated anti-PFDN2 antibody levels. This finding was independent of the SNP, which tags HLA-DRB1*16:02 previously shown to be protective for T2DM. 15 The differences in anti-PFDN2 antibody levels among cases and controls were most prominent in adults with earlier onset ( To our knowledge, PFDN2 has not been previously associated with T2DM. PFDN2 is one of the subunits of prefoldin, a molecular chaperone that facilitates proper protein folding through binding to newly unfolded proteins or through preventing protein aggregation. 35 The mechanism by which these autoantibodies form is unknown. then even low prevalence biomarkers may be useful in identifying those who might potentially benefit from targeted prevention efforts or treatment using either currently available diabetes medications or emerging immunotherapies. Like GAD65 antibody in T1DM, which is a continuous variable and whose prevalence varies with the cutoff selected, 39 the prevalence of anti-PFDN2 antibody may also be higher (or lower) depending on the choice of cutoff.
Since other autoantibodies (eg, IA-2 in T1DM) are known to decline rapidly with increasing duration of disease, 40 we restricted cases to participants with known T2DM duration of less than 5 years with most of our cases having antibodies measured at the time of diagnosis. However, it is also possible that presence of these antibodies, similar to GAD65 antibodies in T1DM, persist despite longer disease duration. 40 It is also possible that these autoantibodies may increase with diabetes duration as more epitopes are exposed by worsening adipose tissue inflammation and declining beta cell function.
Lower anti-PPARG2 antibody was also found to be associated with the SNP protective for T2DM that tags HLA-DRB1*16:02 indicating that the HLA haplotype may be influencing propensity to produce this antibody. PPARG2 is highly expressed in adipose tissue, 41 and it is possible that the antibodies may develop from apoptotic adipocytes.
However, anti-PPARG2 antibody was not significantly associated with T2DM and the importance of anti-PPARG2 antibody is unclear.
Several limitations should be acknowledged. First, this study was performed in a population with a high risk of T2DM. Although the pathophysiology of the development of diabetes in SAIs mirrors those of other populations, the autoantibody associations described may be unique to this population. We also did not measure T1DM associated antibodies, although levels of these antibodies were not different between cases and controls in our prior study of these protein targets 24 and that these antibodies are uncommon in the SAI population. [15] [16] [17] Furthermore, the clinical phenotype in the SAI population is most consistent with T2DM. Whereas individuals with T1DM or latent autoimmune diabetes in adults are often lean, affected individuals in this SAI population have greatly increased adiposity and reduced insulin action and typically go for years without an absolute need for insulin treatment. 42 Because of the cross-sectional design of this study, it is not known if antibodies developed before or after the onset of T2DM. In addition, it is also unclear if anti-PFDN2 antibodies are elevated alongside inflammatory biomarkers such as C-reactive protein, which are also associated with increased risk of T2DM, 43 since such markers were not available in the current study.
It is also unknown whether the same results would have been obtained using other methods such as a radioligand-binding assay, western blot, and ELISA. This study involved a microsphere-based assay that has the advantages of using small volumes to target multiple autoantibodies simultaneously in the same sample. Compared with western blot, which cannot detect conformational epitopes since the target protein is denatured, and ELISA, which may introduce distortions of the 3-dimensional protein structure following protein binding to the plastic well, this bead-based approach is thought to have less distortion effects on target proteins 44 and has been used successfully to detect autoantibodies in autoimmune diseases such as celiac disease and anti-phospholipid disease. 45 In summary, anti-PFDN2 antibodies were increased in participants with recently diagnosed T2DM, a finding that further supports the role of autoimmunity in T2DM. This association was driven by higher antibodies in those with younger onset T2DM indicating a greater role for adaptive immunity in earlier onset disease. In order for investigational therapies for T2DM targeting the immune system to reach the bedside, new autoimmunity biomarkers, such as anti-PFDN2 antibody, may be useful as indicators of disease.
